What is the 13F Pro Quality Score for BSX?

13F Pro ranks BOSTON SCIENTIFIC CORP (BSX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BSX's current score at https://13fpro.ai/company/BSX (free sign-up required for the full ranking).

Which hedge funds own the most BSX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BSX include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/BSX as soon as new 13F filings post.

Where does 13F Pro source BSX data?

All BOSTON SCIENTIFIC CORP fundamentals and ownership data come directly from SEC EDGAR. BOSTON SCIENTIFIC CORP files with the SEC under CIK 885725. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BSX in?

BOSTON SCIENTIFIC CORP (BSX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives BSX's revenue?

Per BOSTON SCIENTIFIC CORP's latest 10-Q filed with the SEC on 2026-08-03, the biggest revenue drivers are: Cardiovascular ($3,624M, +8.3% YoY); MedSurg ($1,818M, +5.9% YoY); Interventional Cardiology & Vascular Therapies ($1,333M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/BSX.

What are BSX's largest expenses?

BOSTON SCIENTIFIC CORP's latest 10-Q reports these as the largest expense items: Selling, general and administrative expenses ($1,803M, +5% YoY); Cost of products sold ($1,594M, -$43M YoY); Research and development expenses ($554M, +5% YoY). Sourced directly from SEC EDGAR filing text for Q2 2026 (quarter ended June 30, 2026).

How often is BSX research updated on 13F Pro?

BSX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BOSTON SCIENTIFIC CORP(BSX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 885725 BSX stock profile & AI dashboard →

13F Pro Quality Score

77.5/100

Rank #66 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

77.0/100

Profitability

80.9/100

Balance Sheet

82.1/100

Earnings Quality

67.7/100

Free Cash Flow

68.9/100

Institutional Flow

80.2/100

Revenue Scale

92.8/100

Dilution Risk

46.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BSX Scores 78/100

exact factor attribution · 2026-09-11

BSX's composite is driven by scale and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+6.4 pts

93th pct

Revenue growth

+5.4 pts

77th pct

Profitability

+4.6 pts

81th pct

Capital efficiency

+3.2 pts

82th pct

Free cash flow

+2.8 pts

69th pct

Earnings growth

+1.9 pts

88th pct

Earnings quality

+1.8 pts

68th pct

Institutional flow

+1.5 pts

80th pct

Shareholder dilution

-0.2 pts

47th pct

Latest change (2026-08-03): 80 → 75 · ↓ Revenue growth 79→62; ↓ Earnings growth 85→71

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in BSX

Events flagged as statistical outliers against BSX's own multi-year baseline — not fixed dollar thresholds.

Insider cluster2026-08-25
4 insiders bought $9,486,038 of BSX in 30 days — 6.3σ above this company's 2-year norm
View source filing →
Insider cluster2026-08-05
3 insiders bought $9,385,631 of BSX in 30 days — 4.7σ above this company's 2-year norm
View source filing →
Insider cluster2026-08-04
3 insiders bought $9,285,694 of BSX in 30 days — 4.7σ above this company's 2-year norm
View source filing →
Record insider buy2026-08-03
Largest insider buy on record for BSX: Mahoney Michael F (Chairman, President & CEO) purchased $9,001,408
View source filing →

BSX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for BOSTON SCIENTIFIC CORP (BSX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BSX at 77.5/100 on a 32-signal composite quality model, placing it at rank #66 of 2,961 stocks — the top 5% of the AI-ranked universe. BSX scores in the top quartile across revenue scale (92.8), balance sheet strength (82.1), profitability (80.9). Shareholder dilution risk is elevated at 46.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BOSTON SCIENTIFIC CORP reports quarterly revenue of $5.4B, net income of $905.0M, an operating margin of 21.6%. Top institutional holders of BSX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. BSX trades on the NYSE exchange and files with the SEC under CIK 885725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BSX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BOSTON SCIENTIFIC CORP directly from SEC EDGAR. BOSTON SCIENTIFIC CORP's 13F Pro composite quality score has ranged between 47 and 79 since 2021, currently 77.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about BOSTON SCIENTIFIC CORP

Quirks, history, and lore behind BSX — the kind of stuff that makes a stock memorable.

1
The Basics
A U.S. healthcare company · large-cap · listed on the NYSE · headquartered in Massachusetts.
2
The Numbers
Annual revenue of roughly $14 billion, with products sold in more than 130 countries — keeping hearts, lungs, and other organs in line, literally.
3
The History
Founded in 1979 by two entrepreneurs who saw a gap in the market for less invasive medical devices, growing from a small startup into a global giant through dozens of acquisitions.
4
The Secret
Its bread and butter is minimally invasive procedures — tiny devices threaded through your body so surgeons don't have to crack you open like a walnut.
5
The Lore
Its stent technology helped spark a revolution in cardiology in the 1990s, and a high-profile legal battle with Johnson & Johnson over stent patents became one of the most-watched feuds in medical device history.
6
The Giveaway
If you or someone you love has had a cardiac stent, a pacemaker, or a procedure to zap an irregular heartbeat, there's a good chance the little gadget doing the work has a BSX pedigree.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving BSX's Business? Latest 10-Q Breakdown

✓ 27/27 datapoints verified

AI-extracted from BOSTON SCIENTIFIC CORP's 10-Q filed 2026-08-03 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 net sales rose 7.5% to $5.442B on Interventional Cardiology and Electrophysiology strength, with gross margin up to 70.7% and operating income of $1.178B.

Biggest Revenue Drivers

Cardiovascular$3,624M+8.3% YoY

Growth led by coronary therapies franchise with AGENT Drug-Coated Balloon and Electrophysiology led by Farapulse PFA System

MedSurg$1,818M+5.9% YoY

Endoscopy biliary franchise and Neuromodulation pain portfolio growth, partly offset by flat Urology

Biggest Revenue Drivers

Total revenue: $5.442B+7.5% YoY

Cardiovascular$3,624M+8.3% YoY

Growth led by coronary therapies franchise with AGENT Drug-Coated Balloon and Electrophysiology led by Farapulse PFA System

Within Cardiovascular

Interventional Cardiology & Vascular Therapies$1,333M

Led by AGENT Drug-Coated Balloon

Electrophysiology$916M

Led by Farapulse Pulsed Field Ablation System, impacted by increased competition

MedSurg$1,818M+5.9% YoY

Endoscopy biliary franchise and Neuromodulation pain portfolio growth, partly offset by flat Urology

Within MedSurg

Endoscopy$793M+7.6% YoY

Driven by biliary franchise led by AXIOS Stent and Delivery System and core GI franchise

Largest Expense Items

Selling, general and administrative expenses$1,803M+5% YoY

Primarily driven by selling expenses associated with higher net sales; 80 bps lower as a percentage of net sales

Cost of products sold$1,594M-$43M YoY

Benefited from IEEPA tariff refund and a decrease in inventory charges

Research and development expenses$554M+5% YoY

Investments across businesses to maintain a product pipeline contributing to future sales growth

Amortization expense$233M+3.4% YoY

Reflects intangibles from recent acquisitions

Margins: Gross margin rose to 70.7% from 67.7%, driven by higher-margin product mix, an $83M IEEPA tariff refund and lower inventory charges, slightly offset by unfavorable foreign currency.

Watch Items from the Filing

Pending $14.5B Penumbra acquisition drew an FTC Second Request; funding includes ~$11.0B of cash and new debt plus stock, backed by a $6.000B term loan facility.
New 2026 Restructuring Plan approved July 21, 2026: pre-tax charges of $700M-$800M, $600M-$700M in cash outlays, targeting ~$500M lower gross annual pre-tax expenses.
Securities class action and four derivative suits filed over the February 4, 2026 stock drop tied to U.S. electrophysiology growth guidance; damages unspecified.
Litigation-related net charges of $76M recorded in the quarter; legal accrual rose to $282M from $242M, and federal spinal cord stimulator cases were consolidated into an MDL.
Cardiac Rhythm Management sales fell to $585M from $590M and Urology grew just 1.1%, hurt by China volume-based procurement and sacral neuromodulation commercial disruption.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$5.4B

Net Income

Q2 2026

$905.0M

Free Cash Flow

Q2 2026

$1.3B

Operating Margin

Q2 2026

21.6%

ROIC

Q2 2026

12.6%

D/E Ratio

Q2 2026

0.51

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+19.9% YoY

$20.07BFY 2025

FY22 $12.68BFY23 $14.24BFY24 $16.75BFY25 $20.07B

Operating Income

+38.8% YoY

$3.61BFY 2025

FY22 $1.65BFY23 $2.34BFY24 $2.60BFY25 $3.61B

EPS (Diluted)

+55.2% YoY

$1.94FY 2025

FY22 $0.45FY23 $1.07FY24 $1.25FY25 $1.94

Total Assets

+10.9% YoY

$43.67BFY 2025

FY22 $32.47BFY23 $35.14BFY24 $39.40BFY25 $43.67B

Total Debt

+6.4% YoY

$11.44BFY 2025

FY22 $8.94BFY23 $9.10BFY24 $10.75BFY25 $11.44B

Op. Cash Flow

+32.0% YoY

$4.53BFY 2025

FY22 $1.53BFY23 $2.50BFY24 $3.44BFY25 $4.53B

Free Cash Flow

+38.3% YoY

$3.66BFY 2025

FY22 $938.0MFY23 $1.79BFY24 $2.65BFY25 $3.66B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$20.07B +19.9%	$16.75B +17.6%	$14.24B +12.3%	$12.68B +6.7%	$11.89B +19.9%	$9.91B
Operating Income	$3.61B +38.8%	$2.60B +11.1%	$2.34B +42.1%	$1.65B +37.5%	$1.20B +1598.8%	$-80.0M
EPS (Diluted)	$1.94 +55.2%	$1.25 +16.8%	$1.07 +137.8%	$0.45 -34.8%	$0.69 +962.5%	$-0.08
Total Assets	$43.67B +10.9%	$39.40B +12.1%	$35.14B +8.2%	$32.47B +0.7%	$32.23B +4.7%	$30.78B
Total Debt	$11.44B +6.4%	$10.75B +18.1%	$9.10B +1.9%	$8.94B -1.4%	$9.06B -0.9%	$9.14B
Operating Cash Flow	$4.53B +32.0%	$3.44B +37.2%	$2.50B +64.0%	$1.53B -18.4%	$1.87B +24.0%	$1.51B
Free Cash Flow	$3.66B +38.3%	$2.65B +47.6%	$1.79B +91.0%	$938.0M -28.7%	$1.32B +16.3%	$1.13B

Get alerted when BSX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BOSTON SCIENTIFIC CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BSX

BlackRock, Inc.
$5.5B129,680,916 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.1B97,087,553 sh
STATE STREET CORP
$3.0B70,111,196 sh
PRIMECAP MANAGEMENT CO/CA/
$2.2B50,520,914 sh
FMR LLC
$2.0B45,702,845 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$1.5B24,859,191 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.4B33,440,102 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.3B29,792,794 sh
D. E. Shaw & Co., Inc.
$1.1B25,457,409 sh
JPMORGAN CHASE & CO
$1.0B23,907,838 sh

Fund	Value	Shares
BlackRock, Inc.	$5.5B	129,680,916
VANGUARD CAPITAL MANAGEMENT LLC	$4.1B	97,087,553
STATE STREET CORP	$3.0B	70,111,196
PRIMECAP MANAGEMENT CO/CA/	$2.2B	50,520,914
FMR LLC	$2.0B	45,702,845
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$1.5B	24,859,191
GEODE CAPITAL MANAGEMENT, LLC	$1.4B	33,440,102
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.3B	29,792,794
D. E. Shaw & Co., Inc.	$1.1B	25,457,409
JPMORGAN CHASE & CO	$1.0B	23,907,838

Companies Similar to BSX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MDT

Medtronic plc

AI score

Very similar · 29 shared holders

Capital World Investors Capital Research Global Investors National Pension Service

STE

STERIS plc

AI score

Very similar · 25 shared holders

VOLORIDGE INVESTMENT MANAGEMENT, LLC Clearbridge Investments, LLC PFA Pension, Forsikringsaktieselskab

SYK

STRYKER CORP

AI score

Very similar · 34 shared holders

Capital Research Global Investors 1832 Asset Management L.P.Clearbridge Investments, LLC

AMGN

AMGEN INC

AI score

Very similar · 31 shared holders

PRIMECAP MANAGEMENT CO/CA/Capital World Investors Capital Research Global Investors

IDXX

IDEXX LABORATORIES INC /DE

AI score

Very similar · 25 shared holders

Capital Research Global Investors Clearbridge Investments, LLC CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

ABT

ABBOTT LABORATORIES

AI score

Very similar · 43 shared holders

Capital Research Global Investors 1832 Asset Management L.P.Holocene Advisors, LP

ISRG

INTUITIVE SURGICAL INC

AI score

Very similar · 45 shared holders

Capital World Investors Capital Research Global Investors Clearbridge Investments, LLC

VRTX

VERTEX PHARMACEUTICALS INC / MA

AI score

Very similar · 31 shared holders

Capital World Investors Capital Research Global Investors Clearbridge Investments, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BSX on your watchlist

Track score changes the day BOSTON SCIENTIFIC CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BSX a good stock to buy?

13F Pro's AI-powered analysis of BOSTON SCIENTIFIC CORP (BSX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BSX are available on the BSX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BSX is classified as a large company.

Which hedge funds own BSX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BSX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BOSTON SCIENTIFIC CORP's investment landscape.